key: cord-0978442-6e637knz
authors: Tsalouchos, Aris; Rossolini, Gian Maria; Maggi, Laura; Mazzoni, Alessio; Annunziato, Francesco; Dattolo, Pietro Claudio
title: COVID‐19 in a kidney transplant recipient after mRNA‐based SARS‐CoV‐2 vaccination
date: 2021-06-13
journal: Transpl Infect Dis
DOI: 10.1111/tid.13649
sha: f4d548f41ebda5983f2876f08aecb81ec008206c
doc_id: 978442
cord_uid: 6e637knz

Immunocompromised patients, including solid organ transplant recipients (SOTRs), were not included in the two large trials of Pfizer/BioNTech and Moderna mRNA vaccines, and therefore, safety and efficacy data are lacking in this population. Recently, immunogenicity, at a median of 29 days, after dose 2 of the mRNA SARS-CoV-2 vaccines have been studied among 658 SOTRs. 46% of participants did not mount anti spike antibody responses suggesting that such patients may remain at high risk for COVID-19 despite vaccination.

To the Editor, 

The author(s) received no financial support for the research, authorship, and/or publication of this article.

The authors of this manuscript have no conflicts of interest to disclose.

PBMCs were stimulated in vitro with medium (RPMI plus 5% human AB serum) or with SARS-CoV-2 S, N, and M proteins peptide pool (Miltenyi Biotech) for 6 h. Then CD3 + CD4 + T cells were evaluated by flow cytometry for CD154 expression and IFNγ and IL-2 intracellular production 

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Genetic epidemiology of variants associated with immune escape from global SARS-CoV-2 genomes. bioRxiv

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants